Analytical Data
-
Gene name
MERTK/Mer
- Application
-
Alternative Names
(Proto-oncogene c-Mer) (Receptor tyrosine kinase MerTK)
-
Species
Human
-
Source
HEK293
-
Tag
C- His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q12866
-
Expression Region
21-505aa
-
Molecular Weight
55.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on MERTK (Mer Tyrosine Kinase), a member of the TAM receptor tyrosine kinase family, focuses on its critical role in regulating immune responses, particularly within the contexts of macrophage activation and resolution of inflammation. MERTK is primarily expressed in macrophages and plays a pivotal role in mediating the phagocytosis of apoptotic cells, thus contributing to tissue homeostasis and the prevention of autoimmune diseases. The receptor’s activation triggers various signaling pathways that promote immune tolerance and suppress pro-inflammatory responses. Recent studies have highlighted MERTK's potential as a therapeutic target in cancer, given its involvement in tumor microenvironment modulation and immune evasion by cancer cells. This has spurred interest in the development of recombinant proteins that can act as agonists or antagonists of MERTK, aiming to enhance anti-tumor immunity or mitigate excessive inflammation. The recombinant MERTK proteins are being engineered for better specificity, stability, and efficacy in therapeutic applications, pushing forward our understanding of immune regulation and the potential for treating a range of diseases including cancer, autoimmune disorders, and chronic inflammatory conditions. Understanding the structure-function relationship of MERTK through these recombinant proteins offers valuable insights into its biology and paves the way for innovative clinical interventions that harness the immune system more effectively.
